Company Profiles

driven by the PitchBook Platform

Permeon Biologics

Description

Developer of new generation of therapeutic drugs created to enhance human health. The company's novel Intraphilin Technology Platform is based on identifying naturally occurring human "supercharged proteins" with the specific ability to activate cell uptake and rapidly permeate to function inside cells and enables functional proteins to replace or restore defective pathways inside cells that cause disease.

2008

Founded

OOB

Status

Out of Business

Latest Deal Type

$12M

Total Amount Raised

Description

Developer of new generation of therapeutic drugs created to enhance human health. The company's novel Intraphilin Technology Platform is based on identifying naturally occurring human "supercharged proteins" with the specific ability to activate cell uptake and rapidly permeate to function inside cells and enables functional proteins to replace or restore defective pathways inside cells that cause disease.

Website:

www.permeonbio.com

Formerly Known As

Newco LS15

Ownership Status

Out of Business

Financing Status

Formerly VC-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

One Kendall Square Building 1400 West, Suite 14203 Cambridge, MA 02139United States
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Permeon Biologics's full profile, request a free trial.

    Permeon Biologics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Permeon Biologics Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Permeon Biologics Executive Team (1)

    NameTitleBoard
    Seat
    Contact
    Info
    John RippleChief Executive Officer
    John Ripple Chief Executive Officer
    Request full access to PitchBook